The aim of this study was to identify the mode of presentation and incidence of @entity14 in pregnancy (CRC-p), assess the outcomes of the mother and foetus according to gestational age, treatment delivered and @entity5 features and location. A systematic review of the literature was carried out to identify studies reporting on CRC-p and pooled analysis of the reported data. Seventy-nine papers reporting on 119 @entity1 with unequivocal CRC-p were included. The calculated pooled risk is 0.002% and age at diagnosis has decreased over time. The median age at diagnosis was 32 (range, 17-46) years. Twelve per cent, 41 and 47% of CRC-p were diagnosed during the first, second and third trimester. The CRC-p site was the colon in 53.4% of cases, the rectum in 44% and multiple sites in 2.6%. Bleeding occurred in 47% of @entity1 , @entity490 in 37.6%, @entity1142 in 14.1%, obstruction in 9.4% and perforation in 2.4%. Out of 82 @entity1 whose treatment was described, 9.8% received chemotherapy during pregnancy. None of their newborns developed @entity2319 , one developed @entity1375 and 72% of newborns were alive. Vaginal delivery was possible in 60% of cases. Anterior resection was performed in 30% of @entity1 and abdominoperineal excision of the rectum in 14.9%. Five @entity1 had either synchronous (60%) or metachronous liver resection (40%). The median survival in these @entity1 was 42 (0-120) months. Fifty-five per cent of @entity1 were alive at the last available follow-up. The median survival of the mother was 36 (0-360) months. @entity1 with @entity5 had longer survival compared with @entity1 with @entity694 (P=0.0072). CRC-p is rare, leading to symptoms being overlooked, and diagnosis made at advanced stages. Cases described in the literature include @entity1 who had @entity5 before pregnancy or developed it after delivery. Survival has not increased over time and the management of these @entity1 requires collaboration between specialties and active interaction with the @entity1 .

XXXX diagnosed during pregnancy: systematic review and treatment pathways.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1375 :: ('MESH:D007037', 'Disease') :: ['hypothyroidism'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'rectal cancer'] @entity694 :: ('MESH:D003110', 'Disease') :: ['colon cancer'] @entity2319 :: ('MESH:D003638', 'Disease') :: ['permanent disability'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain'] @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation']
@entity14 :: (MESH:D015179,Disease) :: ['Colorectal cancer']
